Thermo Fisher To Dominate Transplant Dx Market With $925 Million One Lambda Purchase
This article was originally published in The Gray Sheet
Deal gives Thermo broad access to $480 million global transplant diagnostics market, a segment growing at a mid- to high-single-digit percentage rate.
You may also be interested in...
Thermo Fisher acquires Life Technologies. Mako acquires Stanmore Implants as part of a settlement between the robot-makers. More news.
Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.
Thermo Fisher Scientific wants to claim a dominant share of the budding in vitro allergy testing market segment in the U.S. with its planned $3.5 billion acquisition of Swedish firm Phadia, announced May 19.